A Prospective Study on the Effects of Sacubitril/Valsartan Sodium on Vascular Endothelial Function in Hypertensive Patients with Diabetes Mellitus

A Prospective Single-Arm Study to Evaluate the Effects of Sacubitril/Valsartan Sodium on Vascular Endothelial Function in Patients with Hypertension and Diabetes Mellitus - A Prospective Single-Arm Study to Evaluate the Effects of Sacubitril/Valsartan Sodium on Vascular Endothelial Function in Patients with Hypertension and Diabetes Mellitus

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000057642

Enrollment

Registered

2025-04-17

Start date

2025-10-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

Sacubitril valsartan will be administered for a total of 48 weeks. Dosage is for use as per the package insert.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients age 20 years and older

Exclusion criteria

Exclusion criteria: 1)Those who refused to participate in the study 2)Those not indicated for sacubitril valsartan 3) Patients with severe hepatic impairment 4)Other patients deemed inappropriate by the investigator

Design outcomes

Primary

Measure	Time frame
Changes in FMD values before and after the use of sacubitril valsartan sodium in diabetic patients with hypertension	—

Countries

Japan

Contacts

Public ContactTakanobu Saheki

Kagawa University Hospital Department of Clinical Laboratory

saheki.takanobu@kagawa-u.ac.jp087-891-2230

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026